Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 93
- Registration Number
- NCT00635609
- Locations
- 🇺🇸
Warner Chilcott Investigational Site, Rochester, New York, United States
Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2011-10-28
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 285
- Registration Number
- NCT00619957
- Locations
- ðŸ‡ðŸ‡º
Research Facility, Budapest, Hungary
🇬🇧Research Site, Sheffield, United Kingdom
Treatment of Moderate to Severe Facial Acne Vulgaris
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2013-04-22
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 257
- Registration Number
- NCT00612573
- Locations
- 🇺🇸
Warner Chilcott Investigational Site, Spokane, Washington, United States
Bone Microarchitecture in Osteopenic Postmenopausal Women
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2013-04-22
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 13
- Registration Number
- NCT00577395
- Locations
- 🇦🇷
Research Facility, Buenos Aires, Argentina
🇺🇸Research Site, Cincinnati, Ohio, United States
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 32
- Registration Number
- NCT00577850
- Locations
- 🇺🇸
Research Facility, Gainesville, Florida, United States
🇺🇸Research Site, New Orleans, Louisiana, United States
Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 370
- Registration Number
- NCT00577837
- Locations
- 🇵🇱
Research Facility, Bialystok, Poland
🇵🇱Research Site, Wroclaw, Poland
Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2011-09-28
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 32
- Registration Number
- NCT00577421
- Locations
- 🇸🇪
Research Facility, Goteborg, Sweden
🇦🇺Research Site, Concord, Australia
Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2011-09-16
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 301
- Registration Number
- NCT00577473
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
🇺🇸Research Facility, Falls Church, Virginia, United States
Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 181
- Registration Number
- NCT00577720
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
🇺🇸Research Facility, San Antonio, Texas, United States
Asacol Acute Diverticulitis(DIVA)Study
- Conditions
- Diverticulitis
- Interventions
- Drug: PlaceboDrug: ProbioticDrug: MesalamineOther: Dietary AdviceDrug: Antibiotic for Diverticulitis
- First Posted Date
- 2007-11-06
- Last Posted Date
- 2013-04-22
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 117
- Registration Number
- NCT00554099
- Locations
- 🇺🇸
Research Facility, Monroe, Wisconsin, United States
🇺🇸Research Site, Chesapeake, Virginia, United States